曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴 血脂异常的临床疗效

目的 分析曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床疗效和安全性。方法 选取我院2018年5月~9月收治的冠心病心绞痛伴血脂异常患者70例，随机分为治疗组和对照组，各35例，对照组患者使用曲美他嗪治疗，治疗组在对照组基础上联合阿托伐他汀钙治疗，检测两组患者血清总胆固醇、甘油三酯、高密度脂蛋白和低密度脂蛋白水平，比较两组治疗总有效率及不良反应情况。结果 治疗组血清总胆固醇、甘油三酯和低密度脂蛋白水平分别为（1.25±0.35）mmol/L、（4.89±0.45）mmol/L、（3.24±0.68）mmol/L，均低于对照组的（2.35±0.48）mmol/L、（6.01±0.51）mmol/L、（4.21±0.59）mmol/L，差异有统计学意义（P＜0.05）；治疗组高密度脂蛋白水平为（1.35±0.23）mmol/L，高于对照组的（0.95±0.18）mmol/L，差异有统计学意义（P＜0.05）；治疗组总有效率为94.29%，高于对照组的74.29%，差异有统计学意义（P＜0.05）；治疗组不良反应发生率为2.85%，低于对照组的31.42%，差异有统计学意义（P＜0.05）。结论 曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常患者临床效果更佳，可有效改善患者血脂异常情况，且不良反应少，安全性高。

Clinical Efficacy of Trimetazidine Combined with Atorvastatin Calcium in the Treatment of Coronary Heart Disease Angina Pectoris with Dyslipidemia

Abstract:Objective To analyze the clinical efficacy and safety of trimetazidine combined with atorvastatin calcium in the treatment of angina pectoris with dyslipidemia.Methods 70 patients with coronary heart disease angina pectoris and dyslipidemia were enrolled in our hospital from May to September 2018.They were randomly divided into treatment group and control group, 35 cases in each group. The control group was treated with trimetazidine. The treatment group was treated with atorvastatin calcium based on control group. The serum total cholesterol, triglyceride, high-density lipoprotein and low-density lipoprotein levels were measured in the two groups, and the total effective rate and adverse reactions were compared between two groups. Results The serum total cholesterol, triglyceride, and low-density lipoprotein levels in the treatment group were （1.25±0.35）mmol/L,（4.89±0.45）mmol/L,（3.24±0.68）mmol/L,respectively, which were lower than that in the control group（2.35±0.48）mmol/L,（6.01±0.51）mmol/L,（4.21±0.59）mmol/L,the difference was statistically significant(P<0.05). The high-density lipoprotein in the treatment group was（1.35±0.23）mmol/L,which was higher than that in the control group（0.95±0.18）mmol/L,the difference was statistically significant(P<0.05).The total effective rate of the treatment group was 94.29%, which was higher than that in control group 74.29%,the difference was statistically significant (P<0.05). The incidence of adverse reactions in the treatment group was 2.85%, which was lower than that in the control group 31.42%,the difference was statistically significant (P<0.05).Conclusion Trimetazidine combined with atorvastatin calcium is more effective in the treatment of patients with coronary heart disease angina pectoris and dyslipidemia. It can effectively improve the dyslipidemia of patients with less adverse reactions and high safety.